The FDA assessed the protection and effectiveness of atidarsagene autotemcel depending on knowledge from 37 small children who received atidarsagene autotemcel in two single-arm, open-label clinical trials and in an expanded access system.[7] Young children who gained procedure with atidarsagene autotemcel were in comparison to untreated youngsters